Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    15764728 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Condition: Malignant (Pleural) Mesothelioma
Intervention: Biological: DC + CTX
2 Completed Dendritic Cell-based Immunotherapy in Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: tumor lysate-loaded autologous dendritic cells

Indicates status has not been verified in more than two years